NCT02414139 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG000
- title
- Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)
- description
- Pre-treated patients with MET GCN ≥ 6 and \< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)
- id
- FG001
- title
- Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)
- description
- Pre-treated patients with MET GCN ≥ 4 and \< 6 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG002
- title
- Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)
- description
- Pre-treated patients with MET GCN \< 4 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG003
- title
- Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)
- description
- Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG004
- title
- Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)
- description
- Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)
- id
- FG005
- title
- Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)
- description
- Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)
- id
- FG006
- title
- Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)
- description
- Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)
- id
- FG007
- title
- Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)
- description
- Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)
- id
- FG008
- title
- Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)
- description
- Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)
- id
- FG009
- title
- Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 11
- group Id
- FG001
- num Subjects
- 6
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 14
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 6
- group Id
- FG009
- num Subjects
- 8
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 4
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 4
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 48
- group Id
- FG001
- num Subjects
- 31
- group Id
- FG002
- num Subjects
- 37
- group Id
- FG003
- num Subjects
- 21
- group Id
- FG004
- num Subjects
- 43
- group Id
- FG005
- num Subjects
- 12
- group Id
- FG006
- num Subjects
- 16
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 20
- group Id
- FG009
- num Subjects
- 14
- type
- Progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Protocol deviation
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 5
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 1
- type
- Subject/Guardian decision
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 4
- type
- Study terminated (as per protocol) by Sponsor
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 69
- group Id
- FG001
- num Subjects
- 42
- group Id
- FG002
- num Subjects
- 54
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 69
- group Id
- FG005
- num Subjects
- 15
- group Id
- FG006
- num Subjects
- 28
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 31
- group Id
- FG009
- num Subjects
- 32
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 69
- group Id
- FG001
- num Subjects
- 42
- group Id
- FG002
- num Subjects
- 54
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 69
- group Id
- FG005
- num Subjects
- 15
- group Id
- FG006
- num Subjects
- 28
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 31
- group Id
- FG009
- num Subjects
- 32
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 2
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 4
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 4
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 6
- group Id
- FG001
- num Subjects
- 5
- group Id
- FG002
- num Subjects
- 9
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 15
- group Id
- FG005
- num Subjects
- 4
- group Id
- FG006
- num Subjects
- 5
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 3
- type
- Progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Study terminated by sponsor
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 2
- type
- Subject/guardian decision
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 16
- group Id
- FG003
- num Subjects
- 8
- group Id
- FG004
- num Subjects
- 23
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 8
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 16
- group Id
- FG003
- num Subjects
- 8
- group Id
- FG004
- num Subjects
- 23
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 8
- type
- NOT COMPLETED
- title
- Post-treatment Efficacy Follow-up
- pre Assignment Details
- Screening assessments were conducted up to 28 days prior to the start of study treatment
- recruitment Details
- Participants were enrolled in 95 centers across 20 countries
Complete source fields
- groups
- description
- Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG000
- title
- Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)
- description
- Pre-treated patients with MET GCN ≥ 6 and \< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)
- id
- FG001
- title
- Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)
- description
- Pre-treated patients with MET GCN ≥ 4 and \< 6 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG002
- title
- Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)
- description
- Pre-treated patients with MET GCN \< 4 treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG003
- title
- Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)
- description
- Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)
- id
- FG004
- title
- Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)
- description
- Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)
- id
- FG005
- title
- Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)
- description
- Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)
- id
- FG006
- title
- Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)
- description
- Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)
- id
- FG007
- title
- Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)
- description
- Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)
- id
- FG008
- title
- Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)
- description
- Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)
- id
- FG009
- title
- Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 11
- group Id
- FG001
- num Subjects
- 6
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 14
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 6
- group Id
- FG009
- num Subjects
- 8
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 4
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 4
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 48
- group Id
- FG001
- num Subjects
- 31
- group Id
- FG002
- num Subjects
- 37
- group Id
- FG003
- num Subjects
- 21
- group Id
- FG004
- num Subjects
- 43
- group Id
- FG005
- num Subjects
- 12
- group Id
- FG006
- num Subjects
- 16
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 20
- group Id
- FG009
- num Subjects
- 14
- type
- Progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Protocol deviation
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 5
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 1
- type
- Subject/Guardian decision
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 2
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 4
- type
- Study terminated (as per protocol) by Sponsor
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 69
- group Id
- FG001
- num Subjects
- 42
- group Id
- FG002
- num Subjects
- 54
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 69
- group Id
- FG005
- num Subjects
- 15
- group Id
- FG006
- num Subjects
- 28
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 31
- group Id
- FG009
- num Subjects
- 32
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 69
- group Id
- FG001
- num Subjects
- 42
- group Id
- FG002
- num Subjects
- 54
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 69
- group Id
- FG005
- num Subjects
- 15
- group Id
- FG006
- num Subjects
- 28
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 31
- group Id
- FG009
- num Subjects
- 32
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 2
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 4
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 4
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 6
- group Id
- FG001
- num Subjects
- 5
- group Id
- FG002
- num Subjects
- 9
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 15
- group Id
- FG005
- num Subjects
- 4
- group Id
- FG006
- num Subjects
- 5
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 3
- type
- Progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 1
- type
- Study terminated by sponsor
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 2
- type
- Subject/guardian decision
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 16
- group Id
- FG003
- num Subjects
- 8
- group Id
- FG004
- num Subjects
- 23
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 8
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 16
- group Id
- FG003
- num Subjects
- 8
- group Id
- FG004
- num Subjects
- 23
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 8
- type
- NOT COMPLETED
- title
- Post-treatment Efficacy Follow-up
- pre Assignment Details
- Screening assessments were conducted up to 28 days prior to the start of study treatment
- recruitment Details
- Participants were enrolled in 95 centers across 20 countries
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle